Newsfeeds - Spark Newswire

2 minute read

Earnings

Fulcrum Therapeutics Earnings Perspective: Return On Capital Employed

Today, 11:18 AM

Fulcrum Therapeutics (NASDAQ:FULC) brought in sales totaling $4.93 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 5.53%, resulting in a loss of $20.77 million.

FULC

32 minute read

Earnings Scheduled For November 4, 2021

By Benzinga Insights

Today, 11:18 AM

Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.

AAOI

7 minute read

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline

By Shanthi Rexaline

Today, 11:18 AM

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.

ADPT

2 minute read

Earnings

Fulcrum Therapeutics’s Return On Capital Employed Overview

By Benzinga Insights

Today, 11:18 AM

Benzinga Pro data, Fulcrum Therapeutics (NASDAQ:FULC) reported Q2 sales of $4.38 million. Earnings fell to a loss of $19.68 million, resulting in a 15.48% decrease from last quarter.

FULC

6 minute read

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs

By Shanthi Rexaline

Today, 11:18 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)

ABEO

6 minute read

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data

By Shanthi Rexaline

Today, 11:18 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)

ABSI

1 minute read

News

Fulcrum Therapeutics Announces Multiple Presentations During The Virtual Congress Of The World Muscle Society

By Benzinga Newsdesk

Today, 11:18 AM

Fulcrum Therapeutics, Inc. (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it will present multiple

FULC